(Q36366283)

13 August 2017

1 reference

title

Fibrates in combination with statins in the management of dyslipidemia (English)

1 reference

13 August 2017

1 reference

Terry A Jacobson

1

1 reference

13 August 2017

Franklin H Zimmerman

series ordinal

2

1 reference

13 August 2017

publication date

1 January 2006

1 reference

Journal of Clinical Hypertension

13 August 2017

published in

1 reference

13 August 2017

volume

8

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

35-41; quiz 42-3

1 reference

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Clinical practice. Low HDL cholesterol levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Drug treatment of lipid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Reduction in stroke with gemfibrozil in men with coronary heart disease and low HDL cholesterol: The Veterans Affairs HDL Intervention Trial (VA-HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Rhabdomyolysis and renal failure associated with gemfibrozil monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

A comprehensive description of muscle symptoms associated with lipid-lowering drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Two-year efficacy and safety of simvastatin 80 mg in familial hypercholesterolemia (the Examination of Probands and Relatives in Statin Studies With Familial Hypercholesterolemia [ExPRESS FH]).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Cerivastatin and reports of fatal rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Myopathy and rhabdomyolysis with lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Risk for myopathy with statin therapy in high-risk patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

ACC/AHA/NHLBI clinical advisory on the use and safety of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Mechanistic studies on metabolic interactions between gemfibrozil and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

Combination therapy for dyslipidemia: safety and regulatory considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1524-6175.2005.05278.X

10.1111/J.1524-6175.2005.05278.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference